Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 2:35 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1777–1800 of 3,019 matching trials from the live ClinicalTrials.gov search.
Conditions
Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
Interventions
Gabapentin, Methadone, Oxycodone, Quality-of-Life Assessment, Questionnaire Administration, Venlafaxine, Venlafaxine Hydrochloride Extended Release
Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Buffalo, New York
Conditions
Head and Neck Cancer, Precancerous/Nonmalignant Condition
Interventions
Porfimer Sodium, Photodynamic Therapy
Drug · Procedure
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 120 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Miami, Florida
Conditions
Pancreatic Cancer
Interventions
Gemcitabine, Radiation Therapy, Erlotinib, Surgery
Drug · Radiation · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Houston, Texas
Conditions
Esophageal Cancer
Interventions
cisplatin, docetaxel, irinotecan hydrochloride, radiation therapy
Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
New York, New York
Conditions
Pancreatic Cancer, Gastrointestinal Neoplasms, Colon Rectal Cancer Adenocarcinoma, Esophageal Cancer, Gall Bladder Cancer, Gastric (Stomach) Cancer, Gastrooesophageal Cancer, Gastrointestinal Stromal Tumor (GIST), Hepatobiliary Neoplasm, Liver Carcinoma, Gallbladder Carcinoma, Bile Duct Carcinoma, Carcinoma of the Large Intestine, Anal Cancer
Interventions
Observation
Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Stanford, California
Conditions
Thyroid Cancer
Interventions
Irofulven + capecitabine
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
2
States / cities
Aurora, Colorado • Columbus, Ohio
Conditions
Head and Neck Cancer
Interventions
autologous EBV specific CTLs
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2012
U.S. locations
2
States / cities
Houston, Texas
Conditions
Esophageal Cancer
Interventions
chemotherapy, cisplatin, paclitaxel, low-LET electron therapy, low-LET photon therapy
Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2000
U.S. locations
1
States / cities
New York, New York
Completed Phase 2 Interventional Results available

Studies of Elevated Parathyroid Activity

NCT00001277
Conditions
Hyperparathyroidism, Hypercalcemia, Parathyroid Neoplasm, Multiple Endocrine Neoplasia, MEN1
Interventions
68Ga-Dotatate, 18F-DOPA
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
2 Months and older
Enrollment
1,553 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Completed No phase listed Observational Accepts healthy volunteers

Ultrasound Evaluation of Tongue Movements in Speech and Swallowing

NCT00001167
Conditions
Otorhinolaryngologic Disease, Otorhinolaryngologic Neoplasm, Pharyngeal Neoplasm, Polymyositis, Speech Disorder
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
570 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1979 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Gemcitabine, ACR-368
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Thyroid Nodule, Thyroid Neoplasms, Thyroid Cancer
Interventions
Not listed
Lead sponsor
Boston Medical Center
Other
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Esophageal Cancer
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
Cisplatin, Stereotactic Body Radiation Therapy (SBRT)
Drug · Radiation
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Esophagus Cancer, Esophageal Cancer, Cancer of the Esophagus
Interventions
Intensity Modulated Radiation Therapy, Carboplatin, MD Anderson Symptom Inventory (MDASI)-Plus module, EuroQol (EQ-5D), SF-12, MOS Social Support Measure, CES-D, Blood for ctDNA (optional), Blood for SCCA, Paclitaxel
Radiation · Drug · Other + 1 more
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Squamous Cell Carcinoma
Interventions
No intervention, this is an observational study
Device
Lead sponsor
Zenalux Biomedical, Inc.
Industry
Eligibility
24 Years to 89 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Mouth Neoplasms, Oropharyngeal Neoplasms, Laryngeal Neoplasms, Head and Neck Neoplasms
Interventions
18F-Fluorothymidine PET scan
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Iowa City, Iowa
Conditions
Head and Neck Cancer, Cervical Cancer, Non-small Cell Carcinoma, Melanoma, Ovarian Cancer, Anogenital Cancers, HPV - Anogenital Human Papilloma Virus Infection, HPV-Related Cervical Carcinoma, HPV-Related Carcinoma, HPV-Related Squamous Cell Carcinoma, HPV-Related Malignancy, HPV-Related Adenocarcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Related Adenosquamous Carcinoma, HPV-Associated Vaginal Adenocarcinoma, HPV-Related Endocervical Adenocarcinoma, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Verrucous Carcinoma, HPV-Related Penile Squamous Cell Carcinoma, HPV-Related Vulvar Squamous Cell Carcinoma, HPV Positive Rectal Squamous Cell Carcinoma
Interventions
TSC-204-A0201, TSC-204-C0702, TSC-200-A0201, TSC-204-A0201 + TSC-204-C0702, TSC-204-A0201 + TSC-200-A0201, TSC-204-C0702 + TSC-200-A0201, TSC-204-A0201 + TSC-203-A0201, TSC-204-C0702 + TSC-203-A0201, TSC-200-A0201 + TSC-203-A0201, TSC-203-A0201, TSC-204-A0101, TSC-201-B0702, TSC-204-A0201 + TSC-204-A0101, TSC-204-A0201 + TSC-201-B0702, TSC-204-C0702 + TSC-204-A0101, TSC-204-C0702 + TSC-201-B0702, TSC-200-A0201 + TSC-204-A0101, TSC-200-A0201 + TSC-201-B0702, TSC-203-A0201 + TSC-204-A0101, TSC-203-A0201 + TSC-201-B0702, TSC-202-A0201, TSC-204-A0201 + TSC-202-A0201, TSC-204-C0702 + TSC-202-A0201, TSC-200-A0201 + TSC-202-A0201, TSC-203-A0201 + TSC-202-A0201, TSC-204-A0101 + TSC-202-A0201, TSC-201-B0702 + TSC-202-A0201
Biological
Lead sponsor
TScan Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
21
States / cities
Scottsdale, Arizona • San Diego, California • New Haven, Connecticut + 17 more
Conditions
Non Small Cell Lung Cancer, Cervical Cancer, SCCHN, Pancreatic Cancer, Esophageal SCC, Metastatic Castration-resistant Prostate Cancer, Triple Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Epithelial Ovarian Cancer, Endometrial Cancer, Tissue Factor-Expressing Solid Tumors
Interventions
XB002, Nivolumab, Bevacizumab
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
34
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 25 more
Conditions
Breast Carcinoma, Carcinoma of Unknown Primary, Central Nervous System Carcinoma, Digestive System Carcinoma, Genitourinary System Carcinoma, Head and Neck Carcinoma, Malignant Brain Neoplasm, Malignant Female Reproductive System Neoplasm, Malignant Musculoskeletal Neoplasm, Malignant Solid Neoplasm, Skin Carcinoma
Interventions
Biospecimen Collection, Genetic Testing
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
1,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
2
States / cities
Scottsdale, Arizona • Jacksonville, Florida
Conditions
Head and Neck Cancer
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2030
U.S. locations
1
States / cities
Stanford, California
Conditions
Oral Mucositis
Interventions
SGX942, Placebo
Drug
Lead sponsor
Soligenix
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Lexington, Kentucky
Conditions
Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer, Pancreatic Cancer, Small Intestine Cancer
Interventions
carcinoembryonic antigen peptide 1-6D, incomplete Freund's adjuvant, sargramostim
Biological
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Galveston, Texas
Conditions
Head and Neck Neoplasms
Interventions
bevacizumab
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania